Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ileal bile acid-binding protein (IBABP, also known as FABP6 or gastrotropin) is an intracellular lipid-binding protein highly expressed in the cytosol of enterocytes within the distal small intestine. It plays a critical role in the enterohepatic circulation by binding absorbed conjugated and unconjugated bile acids and facilitating their transcellular movement from the apical to basolateral membrane for re-entry into portal blood. This process maintains systemic cholesterol and bile salt homeostasis. Disruption or deficiency can contribute to malabsorption syndromes or liver diseases associated with impaired enterohepatic cycling[1][4][5]. The original query refers to a physiological process ("bile acid binding in intestine"), but for structured data purposes, it should be mapped specifically to its main molecular mediator—IBABP/FABP6—rather than left as an undefined functional description.
Facilitates transcellular movement of conjugated and unconjugated bile acids from apical to basolateral membrane in enterocytes[1][5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ileal bile acid-binding protein (IBABP (also known as FABP6 in humans)).